OBJECTIVE: The purpose of this study is to establish the feasibility and potential value of measuring the concentration of choline-containing compounds by proton MR spectroscopy (MRS) in musculoskeletal lesions at 3 T. SUBJECTS AND METHODS: Thirty-three subjects with 34 musculoskeletal lesions (four histologically proven malignant, 13 histologically proven benign or proven benign by follow-up analysis, and 17 posttreatment fibrosis with documented stability for 6-36 months) underwent single-voxel 3-T MRS studies. In each case, both water-suppressed and water-unsuppressed scans were obtained. The quality of the scans was recorded as excellent, adequate, or nondiagnostic, and the choline concentration was measured using water as the internal reference. The choline concentrations of benign and malignant lesions were compared using the Mann-Whitney test. RESULTS: Spectral quality was excellent in 26 cases, adequate in four cases, and nondiagnostic in four cases. For malignant lesions (three sarcomas), the choline concentrations were 1.5, 2.9, and 3.8 mmol/kg, respectively. For five benign lesions (two neurofibromas, two schwannomas, and one enchondroma), the choline concentrations were 0.11, 0.28, 0.13, 0.8, and 1.2 mmol/kg, respectively. For seven benign lesions (two hematomas, two bone cysts, one lipoma, one giant cell tumor, and one pigmented villonodular synovitis), the spectra showed negligible choline content. For three posttreatment fibrosis cases, the choline concentration range was 0.2-0.4 mmol/kg. For the remaining 12 posttreatment fibrosis cases, the spectra showed negligible choline content. Average choline concentrations were different for malignant and benign lesions (2.7 vs 0.5 mmol/kg; p = 0.01). CONCLUSION: The measurement of choline concentration within musculoskeletal lesions by MRS is feasible using an internal water-referencing method at 3 T and has potential for characterizing lesions for malignancy.
OBJECTIVE: The purpose of this study is to establish the feasibility and potential value of measuring the concentration of choline-containing compounds by proton MR spectroscopy (MRS) in musculoskeletal lesions at 3 T. SUBJECTS AND METHODS: Thirty-three subjects with 34 musculoskeletal lesions (four histologically proven malignant, 13 histologically proven benign or proven benign by follow-up analysis, and 17 posttreatment fibrosis with documented stability for 6-36 months) underwent single-voxel 3-T MRS studies. In each case, both water-suppressed and water-unsuppressed scans were obtained. The quality of the scans was recorded as excellent, adequate, or nondiagnostic, and the choline concentration was measured using water as the internal reference. The choline concentrations of benign and malignant lesions were compared using the Mann-Whitney test. RESULTS: Spectral quality was excellent in 26 cases, adequate in four cases, and nondiagnostic in four cases. For malignant lesions (three sarcomas), the choline concentrations were 1.5, 2.9, and 3.8 mmol/kg, respectively. For five benign lesions (two neurofibromas, two schwannomas, and one enchondroma), the choline concentrations were 0.11, 0.28, 0.13, 0.8, and 1.2 mmol/kg, respectively. For seven benign lesions (two hematomas, two bone cysts, one lipoma, one giant cell tumor, and one pigmented villonodular synovitis), the spectra showed negligible choline content. For three posttreatment fibrosis cases, the choline concentration range was 0.2-0.4 mmol/kg. For the remaining 12 posttreatment fibrosis cases, the spectra showed negligible choline content. Average choline concentrations were different for malignant and benign lesions (2.7 vs 0.5 mmol/kg; p = 0.01). CONCLUSION: The measurement of choline concentration within musculoskeletal lesions by MRS is feasible using an internal water-referencing method at 3 T and has potential for characterizing lesions for malignancy.
Authors: Laura M Fayad; Nouha Salibi; Xin Wang; Antonio J Machado; Michael A Jacobs; David A Bluemke; Peter B Barker Journal: AJR Am J Roentgenol Date: 2010-01 Impact factor: 3.959
Authors: Laura M Fayad; David A Bluemke; Edward F McCarthy; Kristin L Weber; Peter B Barker; Michael A Jacobs Journal: J Magn Reson Imaging Date: 2006-01 Impact factor: 4.813
Authors: Pedro A Gondim Teixeira; Gabriela Hossu; François Kauffmann; Anou Sewonu; Jean-Marc Constans; Alain Blum; Jacques Felblinger Journal: Eur Radiol Date: 2014-03-16 Impact factor: 5.315
Authors: Ty K Subhawong; Xin Wang; Daniel J Durand; Michael A Jacobs; John A Carrino; Antonio J Machado; Laura M Fayad Journal: AJR Am J Roentgenol Date: 2012-01 Impact factor: 3.959
Authors: L M Fayad; X Wang; J O Blakeley; D J Durand; M A Jacobs; S Demehri; T K Subhawong; T Soldatos; P B Barker Journal: AJNR Am J Neuroradiol Date: 2013-11-28 Impact factor: 3.825
Authors: Shivani Ahlawat; Jaishri Blakeley; Elizabeth Montgomery; Rathan M Subramaniam; Allan Belzberg; Laura M Fayad Journal: Skeletal Radiol Date: 2013-05-07 Impact factor: 2.199